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Ficolins are innate immune components that bind to PAMPs and structures on apoptotic
cells. Humans produce two serum forms (L- and H-ﬁcolin) and a leukocyte-associated
form (M-ﬁcolin), whereas rodents and most other mammals produce ﬁcolins-A and -B,
orthologues of L- and M-ﬁcolin, respectively. All three human ﬁcolins, together with
mouse and rat ﬁcolin-A, associate with mannan-binding lectin-associated serine protea-
ses (MASPs) and activate the lectin pathway of complement on PAMPs. By contrast, mouse
ﬁcolin-B does not bind MASPs and cannot activate complement. Because of these striking
differences together with the lack of functional information for other ﬁcolin-B orthologues,
we have characterized rat ﬁcolin-B, and compared its physical and biochemical properties
with its serum counterpart. The data show that both rat ﬁcolins have archetypal struc-
tures consisting of oligomers of a trimeric subunit. Ficolin-B recognized mainly sialyated
sugars, characteristic of exogenous and endogenous ligands, whereas ﬁcolin-A had a
surprisingly narrow speciﬁcity, binding strongly to only one of 320 structures tested: an
N-acetylated trisaccharide. Surprisingly, rat ﬁcolin-B activated MASP-2 comparable to
ﬁcolin-A. Mutagenesis data reveal that lack of activity in mouse ﬁcolin-B is probably
caused by a single amino acid change in the putative MASP-binding site that blocks the
ﬁcolin-MASP interaction.
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Introduction
Ficolins are pattern-recognition molecules of the innate immune
system that target microbial surfaces and apoptotic cells [1, 2].
They are characterized by an N-terminal collagenous domain and
C-terminal ﬁbrinogen-like domain and assemble into oligomers of
a subunit composed of three identical polypeptide chains.
Humans produce two serum ﬁcolins (L- and H-, also known as
ﬁcolins-2 and -3) together with M-ﬁcolin (or ﬁcolin-1), which has
been localized to the surface of monocytes and identiﬁed in the
secretory granules of neutrophils, monocytes and lung epithelial
cells, as well as in serum at low concentrations [3, 4]. Rodents
and pigs produce only two ﬁcolins: ﬁcolins-A and -B. Based on
their primary structures and chromosomal environments, ﬁcolin-A
is the orthologue of human L-ﬁcolin and ﬁcolin-B corresponds to
human M-ﬁcolin [5]. Nevertheless, there are differences in the
patterns of gene expression, for example, porcine ﬁcolin-B is
synthesized, stored, and secreted by neutrophils, but not by
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is mainly expressed in the bone marrow and spleen [6], as well as
by peritoneal macrophages [7].
Human L-ﬁcolin binds to acetylated compounds, lipoteichoic
acid, a major component of the cell walls of Gram-
positive bacteria and b-D-glucan, a component of yeast cell
surfaces [8–11]. It has several binding sites on each ﬁbrinogen-
like domain: an outer binding pocket, also present in H-
and M-ﬁcolins, together with three unique sites, which form a
continuous binding surface for various acetylated and neutral
carbohydrate ligands. L-ﬁcolin binds to Salmonella typhimurium,
group B streptococci and to various serotypes of S. pneumoniae
and Staphylococcus aureus [12]. It also participates in the clear-
ance of apoptotic and dead host cells [13]. Relatively little is
known about the binding speciﬁcity of H-ﬁcolin. It
has been shown to bind to some carbohydrate ligands, including
D-fucose, and galactose, but failed to recognize any of the ligands
in a large glycan screen, suggesting that carbohydrates
are not its major target [8, 14]. Nevertheless, it has been shown
to bind to the Gram-positive bacterium Aerococcus viridians [15].
M-ﬁcolin binds to acetylated sugars including sialic acid
containing structures and has been shown to target S. aureus
and S. typhimurium. Less is known about the sugar speciﬁcities
of ﬁcolins from other species, although mouse ﬁcolins-A
and -B bound to N-acetylglucosamine (GlcNAc) and
N-acetylgalactosamine when conjugated to BSA and
ﬁcolin-B also bound conjugated sialic-acid containing structures
[16].
All three human ﬁcolins are capable of associating with
mannan-binding lectin (MBL)-associated serine proteases
(MASPs) and activating the lectin branch of the complement
cascade when they bind to microbial targets [17]. MASP-2 alone
is sufﬁcient to activate the lectin pathway by cleaving C4 and
then C2-bound C4b to form the C3 convertase, the central
enzyme in the complement cascade [18]. Recently, MASP-1 has
been shown to cleave factor D, a key enzyme in the alternative
pathway [19]. It also activates human endothelial cells via
protease-activated receptor-4 and in this way regulates endo-
thelia function and may contribute towards development of the
inﬂammatory response [20].
In contrast to human M-ﬁcolin, mouse ﬁcolin-B neither binds
MASP nor activates complement [16]. Furthermore, it
colocalized with lysosomal markers in peritoneal macrophages
suggesting that it may be secreted upon activation of these cells,
or act as an intracellular scavenger to target and facilitate
clearance of PAMP-bearing debris [7]. To determine if lack of
complement activity is unique to mouse ﬁcolin-B or is common in
this class of ﬁcolins, we have characterized rat ﬁcolin-B, which
shares 79 and 88% identity with its human and mouse otholo-
gues, but has not been examined previously. The data show that
rat ﬁcolin-B recognizes ligands found on self-structures as well as
tumour cells and pathogens. Furthermore, it can activate
complement with similar activity to ﬁcolin-A, and thus func-
tionally more closely resembles its human, rather than mouse,
counterpart.
Results
Expression and characterization of rat ﬁcolin-B
To produce pure ﬁcolin-B, free of contamination by ﬁcolin-A or
other serum lectins, recombinant protein was produced using a
mammalian expression system. Initially, it was not clear whether
ﬁcolin-B would be secreted from producing cells or retained
internally, so studies were carried out to follow the kinetics of
biosynthesis, using ﬁcolin-A for comparison. In these experi-
ments, transfected CHO cells were incubated for a brief pulse of
35S-labelled methionine, followed by extended incubation in
unlabelled media. By comparing the amounts of labelled protein
in the intracellular and extracellular fractions over time, the
kinetics of biosynthesis and secretion could be followed. As
shown in Fig. 1, labelled ﬁcolin-B appeared in the culture
medium of producing cells soon after the initial pulse and was
secreted with a half-time of 110minutes. There was no
evidence of retention of ﬁcolin-B within cells, nor of degradation.
The secretion rate is typical of many secreted proteins, including
rat MBL-A and MBL-C (Heise et al. 2000) and was only
slightly slower than ﬁcolin-A (half-time 90minutes). Thus,
Figure 1. Secretion of rat ﬁcolins-A and -B. (A)
35S-Pulse-labelled
ﬁcolins from the intracellular and secreted fractions of transfected
CHO cells were pelleted using GlcNAc Sepharose and analyzed by SDS-
PAGE. Labelled ﬁcolin was quantiﬁed by scanning autoradiographs.
(B) Time-course of secretion for ﬁcolins-A and -B. Data are expressed
relative to the total amount of label incorporated.
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polypeptide are not recognized by CHO cells.
Ficolin-B was harvested from the culture medium of produ-
cing cells and puriﬁed by afﬁnity chromatography on GlcNAc-
Sepharose columns. Yields from several different cell-lines were
relatively low, with only 50–100mg of puriﬁed protein per litre of
culture medium, compared to 4–5mg/L of ﬁcolin-A [21]. Puriﬁed
ﬁcolin-B migrated as two bands on SDS-polyacrylamide gels
under reducing conditions, with apparent molecular masses of 39
and 40kDa (Figs. 1 and 2), both of which are greater than the
molecular mass of 34kDa calculated from the amino acid
sequence. There is one potential N-linked glycosylation site in the
ﬁbrinogen domain and ﬁve potential O-linked sites in the
collagen-like domain, so the two species observed on gels prob-
ably reﬂect different glycoforms. N-terminal sequencing of each
band yielded the sequence: ADTCPEVKVL, indicating that the
signal peptide is cleaved between Ala22 and Ala23 of the
synthesized polypeptide during biosynthesis.
Under non-reducing conditions, ﬁcolin-B migrated as
mixtures of covalently linked polypeptides on SDS-poly-
acrylamide gels ranging from one to more than 12 chains, so
most polypeptides must be linked by interchain disulﬁde bonds
(Fig. 2). It eluted as several overlapping peaks from a gel ﬁltra-
tion column, signifying the presence of different oligomeric
forms. Oligomers were identiﬁed by comparison with the elution
positions of the different forms of ﬁcolin-A, which have
comparable sizes and have been characterized previously [21]. In
this way, two major oligomers were identiﬁed consisting of six
and nine polypeptides (subsequently called dimers and trimers of
subunits), together with smaller amounts of monomers and
tetramers of subunits. Trace amounts of even larger oligomers
were observed, probably comprising pentamers and/or hexamers
of subunits. Analysis of fractions collected across the elution
proﬁle conﬁrmed that the disulphide-bonding pattern in oligo-
mers is heterogeneous (Fig. 2C). For example, fraction 3
comprises mainly trimers of subunits, but a ladder of covalently
linked polypeptides (from 1 to 9) is observed on SDS gels under
non-reducing conditions, indicating that the different forms must
be assembled from combinations of covalently linked polypep-
tides, associated through non-covalent interactions. Overall, the
oligomeric composition is broadly similar to rat ﬁcolin-A, which
also comprises mixtures of disulphide-linked oligomers [21].
Carbohydrate speciﬁcity of rat ﬁcolins
Because little detailed information is known about the binding
speciﬁcities of rat ﬁcolins, we examined their lectin properties
towards a broad screen of endogenous and exogenous carbohy-
drates using the Core H Glycan array technology facility at The
Consortium for Functional Glycomics, Emory University (GA,
USA). Ficolins were labelled with a ﬂuorescent dye and used to
probe a library of 320 ligands (Supporting Information). Ficolin-A
is known to bind to N-acetylated ligands such as GlcNAc [21], but
speciﬁcity towards natural ligands has not been examined.
Surprisingly, it bound appreciably to only one of the ligands
tested: a trisaccharide containing a terminal a1-6 linked GlcNAc
residue (ligand 157) (Fig. 3). No binding was observed towards
ligands lacking the terminal GlcNAc (ligand 153) or when the
GlcNAc was linked via a1-3 (ligand 156), b1-2 (ligand 158), b1-3
(ligand 165) or b1-6 (ligand 176) glycosidic linkages (Table 1).
Thus, the type and mode of attachment of the terminal sugar
Figure 2. Oligomeric structure of rat ﬁcolin-B. (A) Puriﬁed ﬁcolin-B
separated by SDS-PAGE (4–12% gradient gel) under reducing and non-
reducing conditions. Proteins were stained using Coomassie blue.
(B) Gel ﬁltration of ﬁcolin-B on a Superdex-200 column. The elution
positions of monomers (M), dimers (D), trimers (T) and tetramers (Tt) of
rat ﬁcolin-B are indicated. (C) Fractions collected across the gel
ﬁltration peaks were separated by gel electrophoresis on a 4–12%
gradient SDS-polyacrylamide gel under non-reducing conditions, and
proteins were stained with Coomassie blue.
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next best ligand was410-fold lower, certain sialyated sugars
and a disialic acid also bound above background level, neither of
which have been previously identiﬁed as ligands for a ﬁcolin-A
orthologue. Notably, all ligands contained multiple N-acetyl
groups, suggesting that internal acetylated residues may be
recognized by ﬁcolin-A, in addition to the terminal moiety.
In contrast to ﬁcolin-A, rat ﬁcolin-B bound to a number of
ligands in the glycan screen (Table 2), with a marked preference for
sialyated structures with terminal N-acetylneuraminic but not
N-glycolyneuraminic acid (a sialic acid found in many mammals but
not humans; ligands 257–264, Supporting Information). Moreover
mono- and biantennary sialated sugars with a2-3 linkages but not
a2-6 linkages were preferentially recognized (for example, compare
ligands 143, 199 and 54 (Table 2)). Ligands could be divided into
four main groups: di- and trisialic acids; mono- or biantennary
structures containing the trisaccharide sialyl-N-acetyllactosamine
(Sialyl-Gal-GlcNAc), 9-acetylated sialated ligands and more weakly
to certain fucosylated structures. It is notable that such sequences
are commonly found on endogenous structures including cell
surfaces and tumour cells, as well as on exogenous ligands including
pathogenic microbes and viruses [22, 23].
Complement activation
Rat ﬁcolin-A binds MASP and can activate complement [21], but
the properties of ﬁcolin-B are not known. To test binding to
MASP-1 and MASP-2, ﬁcolin-B was immobilized on a sensor chip
and interactions with MASP were monitored using surface
plasmon resonance. Both MASP associated with ﬁcolin-B in the
presence of Ca
21 ions to form relatively stable complexes. As with
ﬁcolin-A, the binding kinetics were complex. The data ﬁtted best
to a two-reaction parallel binding model for MASP-2A (Fig. 4),
with apparent equilibrium dissociation constants KD1 and KD2 of
752 and 23nM. Association rate constants (kon) were 110
4 and
2.610
5M
1s
1 and dissociation rate constants (koff) were
5.810
3 and 610
3s
1, respectively. The kinetics of
MASP-1 binding was similar to MASP-2 (data not shown). KD1
and KD2 were 392 and 8.4nM, with kon values of 2.410
4 and
5.710
5M
1s
1 and koff values of 9.110
3 and 4.310
3s
1,
respectively. The biphasic kinetics are typical of rat MBL-MASP
and ﬁcolin-MASP interactions and probably reﬂect binding of a
second MASP to ﬁcolin oligomers at high MASP concentrations,
although 1:1 complexes predominate under physiological
concentrations [24]. No binding of MASP-1 or MASP-2 was
detected in the presence of EDTA, conﬁrming that the interac-
tions are Ca
21 dependant (data not shown). Overall, the binding
Figure 3. Glycan array screening of rat ﬁcolins-A and -B. Fluorescently
labelled ﬁcolins (200mg/mL) were used to probe the glycan array
comprising 320 ligands. Error bars represent the means7SD of six
measurements. Structures of the best glycan ligands are indicated.
Table 1. Binding of ﬁcolin-A to selected carbohydrate structures
Ligand number Ligand Binding signal Standard error
157 GlcNAca1-6Galb1-4GlcNAcb- 50680 7409
Non-ligands
153 Galb1-4GlcNAcb-3 3 2 4
156 GlcNAca1-3Galb1-4GlcNAcb-9 3 2 9
158 GlcNAcb1-2Galb1-3GalNAca- 155 68
165 GlcNAcb1-3Galb1-4GlcNAcb-9 9 1 2
176 GlcNAcb1-6Galb1-4GlcNAcb-8 4 3 0
Sialated ligands
2 Neu5Aca2-8Neu5Acb- 4003 2270
255 Neu5Acb2-6Galb1-4GlcNAcb- 3714 1022
221 Neu5Aca2-3Galb1-3(Neu5Aca2-6)GalNAca- 2507 1622
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with MASP-2 [21], but markedly different from mouse ﬁcolin-B,
which does not bind MASPs despite a high degree of sequence
identity [16].
MASP-2 in complex with MBL or ﬁcolin is necessary and
sufﬁcient to activate the lectin pathway of complement activa-
tion, so we next examined if rat ﬁcolin-B could activate comple-
ment. Ficolin-B triggered MASP-2K activation, using GlcNAc-
Sepharose as a target, with a half-time of 110min (Fig. 5;
compared to 56min by ﬁcolin-A under comparable conditions
(data not shown)). Very little activation was observed in the
absence of GlcNAc-Sepharose (10% over 16h), and this was no
faster than auto-activation of zymogen MASP-2K alone. Thus,
MASP-2 activation is both target and ﬁcolin dependent (Fig. 5B).
To conﬁrm that MASP activation by ﬁcolin-B leads to complement
activation, we measured deposition of the membrane attack
complex, on acetylated BSA as an activating target. Addition of
recombinant ﬁcolin-B to human serum depleted of endogenous
MBL and ﬁcolins activated complement in a concentration-
dependent manner (Fig. 5C) and with similar activity to ﬁcolin-A.
Thus, rat ﬁcolin-B, unlike its mouse counterpart, activates the
lectin pathway of complement via a comparable mechanism to
ﬁcolin-A (and MBL) in which the ﬁcolin increases the rate of
MASP-2 autolysis, but only when complexes bind to a target
surface.
MASPs bind to a characteristic motif on the collagenous
domain of MBL and ﬁcolins comprising the sequence Hyp-Gly-
Lys-Xaa-Gly-Pro, in which Xaa typically represents a hydrophobic
aliphatic residue or a methionine, and the lysine residue is
essential for binding [21, 24, 25]. To conﬁrm that MASP bind to
the equivalent site in rat ﬁcolin-B, Lys54 and Ala55 within the
sequence Hyp-Gly-Lys-Ala-Gly-Pro were changed to proline and
hydroxyproline residues, respectively (K54P, A55O). The result-
ing mutant (Ficolin-B PO) was expressed and puriﬁed from CHO
cells and resembled WT protein upon gel ﬁltration chromato-
graphy and SDS-PAGE (data not shown), conﬁrming that it
assembles correctly during biosynthesis. However, it failed to
bind MASP-1 or MASP-2 (Fig. 4) and did not activate MASP-2
(Fig. 5), demonstrating that Lys54 and/or Ala55 form part of the
MASP-binding site. Although mouse ﬁcolin-B possesses a similar
binding motif, it is unusual compared to other ﬁcolins because it
contains an acidic residue adjacent to the key lysine: Hyp-Gly-
Lys-Glu-Gly-Pro. In previous work, introduction of a glutamate
into rat ﬁcolin-A reduced the afﬁnity of MASP-binding and
MASP-2 activation by 7-fold, so it is somewhat disruptive [21].
To examine the effect of such a mutation within the ﬁcolin-B
Table 2. Binding of ﬁcolin-B to selected carbohydrate structures
Ligand number Ligand Binding signal Standard error
Sialated ligands
143 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-3Galb1-
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-
30636 5205
255 Neu5Acb2-6Galb1-4GlcNAcb- 23573 9774
219 Neu5Aca2-3Galb1-3(Neu5Aca2-3Galb1-4)GlcNAcb- 18985 5184
238 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb- 7170 4094
199 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-3Galb1-
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-
4591 734
318 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1-
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-
3263 1911
221 Neu5Aca2-3Galb1-3(Neu5Aca2-6)GalNAca- 1528 661
232 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb- 1415 422
Non-ligand
54 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3(Neu5Aca2-6Galb1-
4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-
78 53
9-Acetylated sialated ligands
48 9NAcNeu5Aca- 17882 7296
49 9NAcNeu5Aca2-6Galb1-4GlcNAcb- 5319 2738
Di- and trisialic acids
3 Neu5Aca2-8Neu5Aca2-8Neu5Acb- 16240 8995
2 Neu5Aca2-8Neu5Acb- 11811 6744
252 Neu5Aca2-8Neu5Aca- 3731 2206
Fucosylated ligands
108 Gala1-4(Fuca1-2)Galb1-4GlcNAcb- 3180 1576
69 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAc- 1477 692
290 Gala1-3(Fuca1-2)Galb- 1350 720
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(ﬁcolin-B E). The resulting mutant failed to bind to MASP-1 or
MASP-2 at the highest concentrations tested (0.5mM; Fig. 4),
despite having equivalent structural and lectin properties to WT
ﬁcolin-B. It also failed to activate MASP-2, even after prolonged
incubation (up to 16h), indicating that the glutamate residue
disrupts complement activation by ﬁcolin-B by preventing asso-
ciation with MASP-2 (Fig. 5). Thus, mouse ﬁcolin-B differs from
its human and rat counterparts probably as a result of a single
amino acid substitution in the collagenous domain.
Discussion
This study indicates that rat ﬁcolin-B binds MASP and activates
MASP-2 on a target surface, to trigger complement activation. The
rate of MASP-2 activation was only twofold lower than for rat
ﬁcolin-A, so ﬁcolin-B-mediated complement activation is likely to
be an important physiological activity for neutralizing bacteria. This
work also provides an explanation for the lack of complement
activity of mouse ﬁcolin-B: a glutamate residue in place of the usual
aliphatic/hydrophobic residue in the residual MASP-binding site.
Substitution of a glutamate for the natural alanine residue in rat
ﬁcolin-B completely abolished MASP binding and complement
activation, so the acidic residue is particularly disruptive within the
ﬁcolin-B scaffold, compared to ﬁcolin-A. Mouse ﬁcolin-B is probably
unusual in its lack of complement function, because other ﬁcolins
for which sequences have been determined contain archetypal
MASP-binding sites [21]. This difference is particularly pertinent
for studies using mouse models of lectin pathway function.
The ligand speciﬁcity of rat ﬁcolin-B is distinct from that of
ﬁcolin-A, so each protein targets a different set of physiological
ligands. The ‘‘best’’ ligand of ﬁcolin-A (157, which contains a
terminal a1-6 GlcNac moiety) is not commonly found in mamma-
lian glycans, consistent with its ability to recognize foreign struc-
tures. Some sialated structures were also recognized, but these all
bound relatively weakly. Moreover, ligand 221 (Table 1) is also
atypical of mammalian structures, and the disialic acid (ligand 2,
also recognized by ﬁcolin B) is found on pathogenic bacteria [26].
In contrast, Ficolin-B exclusively recognized terminally sialylated
ligands. Speciﬁcity was restricted to a2-3, b2-6 and a2-8 linkages,
rather than a2-6 linkages. As well as being found on the surface of a
variety of pathogenic microbes, viruses and tumour cells, these
motifs are likely to be markers of normal host cells [22]. For
example, certain pathogenic bacteria (e.g. Escherichia coli K1 and
Neisseria meningitidis) express capsular polysialic acids that help
evade the immune system, and these are chemically identical to
sugars found on neural cell adhesion molecules [26]. Similarly,
9-O-acetylated sialic acids are commonly found in mammalian
sugars, but are also present on pathogens, including parasitic
protozoa and fungi [27, 28]. Given that sialylation is both species
and tissue speciﬁc [29, 30], more detailed analysis of rat glycans is
necessary to fully understand the physiological implications of the
ligand speciﬁcity of rat Ficolin-B. Nevertheless, the likely binding
preference for endogenous as well as exogenous sugar structures,
raises a key unresolved question: how complement activation
leading to self damage is avoided on host tissues? One possibility is
that M-ﬁcolin/ﬁcolin-B are secreted only upon activation of
producing leukocytes, leading to highly localized and/or rapid
release and turnover. Once bound, they could neutralize their
targets either through complement activation or via opsonopha-
gocytosis. Consistent with the latter possibility, M-ﬁcolin undergoes
a conformational change at lower pH, as would be found in lyso-
somes, rendering it incapable of binding to its ligands [31]. While
microbes or apoptotic cell debris are probably destroyed by the cell,
residual M-ﬁcolin may be recycled and deposited back into secre-
tory granules for subsequent use. Although mouse ﬁcolin-B lacks
the ability to activate complement via the lectin pathway, it prob-
ably also functions as an opsonin to clear pathogens and or apop-
totic debris. Notably, it is found in the lysosomes and/or late
endosomes of macrophages, and its production is upregulated upon
macrophage activation [7].
Overall, rat ﬁcolin-B recognizes similar classes of ligands to
human M-ﬁcolin and mouse ﬁcolin-B, but there are notable
differences. For example, both rat and human proteins bound to
Figure 4. MASP-2A binding to immobilized ﬁcolin-B and ﬁcolin-B
mutants using surface plasmon resonance. Equivalent amounts of
ﬁcolin-B and ﬁcolin-B mutants (5000–6000RU) were immobilized on to
a CM5 sensor chip and MASP-2A was injected at 0.04, 0.08, 0.16 and
0.33mM. The dotted line shows the ﬁt to a two-binding site model for
ﬁcolin-B. In ﬁcolin-B PO, Lys54 and Ala55 have been mutated to proline
and hydroxyproline respectively. In ﬁcolin-B E, Ala55 was replaced by a
glutamic acid residue.
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biantennary structures (e.g. ligands 143, 219, 255 and 199),
whereas the latter recognized only one of these with substantial
afﬁnity: ligand 143. By contrast, human ﬁcolin-M bound to several
gangliosides [14], which were not targeted by rat ﬁcolin-B.
A surprising ﬁnding is the narrow carbohydrate speciﬁcity of
rat ﬁcolin-A with only one of the targets binding appreciably
(ligand 157). Although this was also one of the major ligands of
human L-ﬁcolin [9, 14], L-ﬁcolin recognized a variety of other
ligands that were not targeted by the rat protein. Although most
of the residues that form the binding pockets are conserved in rat
ﬁcolin-A, serine residues in site S2 of human L-ﬁcolin, which form
hydrogen bonds via their hydroxyl groups to sugar ligands are
replaced by more bulky threonine and asparagine residues, which
might exclude certain ligands [14]. Another interesting difference
is the weak but signiﬁcant binding of certain sialyated structures
by the rat but not the human protein. Unlike M-ﬁcolin, L-ﬁcolin
does not bind sialyated sugars due to differences at the S1
binding pocket. Notably, the hydroxyl group of a tyrosine residue
at position 271 in M-ﬁcolin provides a direct hydrogen bond to
N-acetylgalactosamine or sialic acid moieties, whereas the
corresponding phenylalanine in L-ﬁcolin cannot make the same
contacts [14]. Rat ﬁcolin-A possesses a tyrosine at this position so
in principal could share some of the properties of M-ﬁcolin, hence
explaining its somewhat different ligand speciﬁcity. Thus, small
differences in the largely conserved binding pockets probably
dictate the subtle binding preferences of these defence lectins.
Material and methods
Cloning, expression and puriﬁcation of rat ﬁcolin-B
The cDNA of rat ﬁcolin-B was ampliﬁed from a rat cDNA library
kindly provided by Prof. Wilhelm Schwaeble (University of
Leicester, UK) using PCR, and was cloned into pGEM-T cloning
vector (Promega). The forward and reverse oligonucleotides
were GAACTCGAGGCCACCATGGTCCTGGGATCTGCT, where
the ribosome-binding site is underlined and the start codon is
in bold, and AGAGAATTCCTAGATGAGGCGCACCTTCAT, where
the stop codon is in bold. The cDNA was cloned into a
mammalian expression vector, pED4 [32], the sequence
conﬁrmed and the resulting construct was introduced into the
CHO cell line DXB11. Production was achieved following
ampliﬁcation using the dihydrofolate reductase inhibitor, metho-
trexate [21]. Culture media were harvested and protein puriﬁed
by afﬁnity chromatography on GlcNAc-Sepharose columns (1-mL
column for 250mL of media) using the strategy described
previously for ﬁcolin-A [21]. We also attempted to express mouse
Figure 5. Kinetics of MASP-2 activation by ﬁcolin-B and ﬁcolin-B mutants. Activation of MASP-2K by WTand mutant ﬁcolins on GlcNAc-Sepharose
as an activating target. (A) Aliquots of protein complexes taken at different time points were analyzed by SDS-PAGE (10% gel), stained with
Coomassie blue. The migration positions of zymogen MASP-K and the N- and C-terminal fragments of activated MASP-2K (activated –N and –C)
are indicated. (B) The amount of activation was determined by measuring cleavage of zymogen MASP-2K. Only 12% cleavage was observed for
either mutant after 16h comparable to the amount of autoactivation of MASP-2K alone. In ﬁcolin-B PO, Lys54 and Ala55 have been mutated to
proline and hydroxyproline, respectively. In ﬁcolin-B E, Ala55 was replaced by a glutamic acid residue. (C) Complement activation by recombinant
rat ﬁcolins-A and -B. Complement activation was measured on acetylated-BSA using an alkaline phosphatase-conjugated antibody speciﬁc for the
membrane attack complex, following incubation of chromogenic substrate. Background absorbance, in the absence of ﬁcolin, was subtracted from
the data. Data are the average7SE from duplicate observations.
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protein was produced from transfected cells, so further analysis
was not possible.
Other protein components
Recombinant rat ﬁcolin-A and modiﬁed forms of rat MASP-2
were produced in a CHO cell-expression system and puriﬁed as
described previously by afﬁnity chromatography on GlcNAc-
Sepharose and nickel-Sepharose columns, respectively [21, 33].
WT rat MASP-1 and MASP-2 are toxic to producing CHO cells
because they autoactivate during biosynthesis. We therefore used
two modiﬁed forms of MASP-2, both of which are secreted as
zymogens and have been characterized with regard to their
structures, activation and catalytic properties [33, 34]. MASP-2A
is a catalytically inactive form in which the active site serine at
position 613 has been replaced by an alanine. MASP-2K is a
catalytically active form, in which the arginine residue at the
cleavage site for zymogen activation (Arg
424) has been changed
to a lysine residue to slow down the rate of spontaneous
autoactivation during biosynthesis. A modiﬁed form of MASP-1,
called MASP-1ent, was used for binding analysis [34]. This is a
catalytically active form in which residues Lys
425–Arg
429,
immediately preceding the cleavage site for zymogen activation,
were replaced with the recognition sequence of the serine
protease enterokinase: Asp-Asp-Asp-Asp-Lys. Binding and activa-
tion assays were carried out using MASP-2A or MASP-1ent and
MASP-2K, respectively. Mutant forms of ﬁcolins were
created by PCR and expressed in the same way as the WT
protein. All mutations were veriﬁed by sequencing of the entire
cDNA, within the expression vector, prior to transfection of the
CHO cells.
N-terminal sequencing
Samples were separated on 10% Novex BIS-TRIS NuPAGE precast
gels using 2-(N-morpholino)ethanesulfonic acid buffer in a
NovexCell II Mini-Cell gel apparatus. The protein bands were
electroblotted onto a Novex 0.2mm polyvinylidene diﬂuoride
membrane (Invitrogen) using the Novex Blot module. The
membrane was stained with Coomassie Brilliant Blue and target
bands were excised, washed with 10% methanol and sequenced
on a 494A Procise protein sequencer (Applied Biosystems,
Warrington, UK) for ten cycles using the standard sequencing
protocol.
Pulse-chase labelling of ﬁcolins
Pulse-chase experiments were carried out essentially as described
in [35]. Brieﬂy, CHO cells producing rat ﬁcolin-A or -B were
grown to conﬂuence in 3510-mm tissue culture dishes
containing 2mL of minimal essential medium-a, lacking nucleo-
sides and supplemented with 10% dialyzed foetal calf serum and
0.5mM methotrexate. Culture medium was changed daily for an
additional 4 days. Before labelling, all culture media were pre-
warmed to 371Ci n5 %C O 2. Cells were incubated with 2mL of
methionine-free medium for 5min to diminish any intracellular
methionine. Labelling was initiated with 1mL of fresh methio-
nine-free medium containing
35S-methionine (56mCi/mL). After
15min, the pulse was terminated by removing the
35S-methio-
nine-containing medium and the cells were incubated with
medium containing a 20-fold excess of unlabelled methionine.
After various time intervals, cells were released from the culture
dish by scraping, pelleted by centrifugation at 2000rpm in a
bench-top centrifuge, and disrupted by resuspension in cell lysis
buffer (50mM Tris-HCl, pH 7.4, containing 500mM NaCl and 1%
Triton X-100). GlcNAc-Sepharose (10mL) was added to each
fraction and mixtures were incubated on ice for 10min. Bound
ﬁcolin was pelleted by centrifugation and separated by SDS-
PAGE. Ficolins were quantiﬁed by scanning autoradiographs
using a ChemiGenius (Syngene).
Glycan array analysis
Alexa Fluor
s 488 tetraﬂuorophenylcarboxylate ester (Invitrogen,
Paisley, UK) was dissolved in DMSO to a ﬁnal concentration of
1mg/mL, and 20mL was added to puriﬁed ﬁcolin (250mLo fa
400mg/mL solution) and incubated for 2h at room temperature.
Excess label was removed by dialysis. The labelled ﬁcolin was
then screened using the Glycan array technology facility at The
Consortium for Functional Glycomics, Emory University. This
facility uses printed glycan microarray chips with 320 different
carbohydrate targets of natural and synthetic glycans attached to
the chip via amino linkers. Binding was detected by measuring
the ﬂuorescence associated with each glycan. In each case,
screening of the whole chip was performed with a total volume of
70mL of 200mg/mL ﬁcolin in 20mM HEPES, pH 7.4, with
140mM NaCl, 5mM CaCl2, and repeated six times. Error bars
represent the average7SE.
Surface plasmon resonance
Measurements were performed using a BIAcore 2000 instrument
(GE Healthcare). Protein ligands were diluted into 10mM sodium
acetate, pH 4.0, and immobilized on to the carboxymethylated
dextran surface of a CM5 sensor chip (GE Healthcare), using
amine coupling chemistry. Binding was measured in 10mM
HEPES (pH 7.4) containing 150mM NaCl and 5mM CaCl2 at a
ﬂow rate of 5mL/min and at 251C. After injection of ligand, the
protein surface was regenerated by injection of 10mLo f1 0 m M
HEPES buffer (pH 7.4) containing 1M NaCl and 5mM EDTA.
Data were analyzed by ﬁtting association and dissociation
curves to Langmuir binding models for several protein concen-
trations simultaneously, using BIAevaluation 4.1 software (GE
Healthcare). Increasingly complex models were tested until a
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dissociation constants (KD) were calculated from the ratio of the
dissociation and association rate constants (koff/kon). Errors were
determined from two separate experiments.
MASP-2 activation assays
Activation was measured by following MASP autolysis as
described previously [34]. Proteins were separated by SDS-PAGE
under reducing conditions and the amount of MASP cleaved was
quantiﬁed by densitometry. Data are the mean7SE from at least
two separate experiments using different protein preparations,
unless otherwise stated.
Complement activation
Complement activation was measured using the Weislab Comple-
ment system MBL pathway kit (Euro-diagnostic). Assays were
conducted as described, with the exception that wells of the
microtitre dish were coated with acetylated-BSA (100mLo f
0.1mg/mL), in 50mM sodium bicarbonate (pH 9.6), overnight at
41C, instead of mannan. Whole human serum was depleted of
endogenous MBL and ﬁcolins before setting up the assay by
passage through two GlcNAc-Sepharose columns (0.5 for 1mL of
serum). Data represent the average7error from duplicate
observations.
Acknowledgements: The authors thank Wilhelm Schwaeble for
providing the rat cDNA library and David Smith at Emory
University for overseeing the glycan-array screening. Funding for
this work was supplied by Grant G0501425 from the Medical
Research Council and Grant 077400 from The Wellcome Trust.
R. W. and D. M. are Research Council U.K. Academic Fellows.
Resources provided by the Consortium for Functional Glycomics
are supported by NIGMS Grant GM62116.
Conﬂicts of interest: The authors declare no ﬁnancial or
commercial conﬂict of interest.
References
1 Matsushita, M. and Fujita, T., Ficolins and the lectin complement
pathway. Immunol. Rev. 2001. 180: 78–85.
2 Runza, V. L., Schwaeble, W. and Mannel, D. N., Ficolins: novel pattern
recognition molecules of the innate immune response. Immunobiology
2008. 213: 297–306.
3 Liu, Y., Endo, Y., Iwaki, D., Nakata, M., Matsushita, M., Wada, I., Inoue, K.
et al., Human M-ﬁcolin is a secretory protein that activates the lectin
complement pathway. J. Immunol. 2005. 175: 3150–3156.
4 Teh, C., Le, Y., Lee, S. H. and Lu, J., M-ﬁcolin is expressed on monocytes
and is a lectin binding to N-acetyl-D-glucosamine and mediates
monocyte adhesion and phagocytosis of Escherichia coli. Immunology
2000. 101: 225–232.
5 Ohashi, T. and Erickson, H. P., Oligomeric structure and tissue distribu-
tion of ﬁcolins from mouse, pig and human. Arch. Biochem. Biophys. 1998.
360: 223–232.
6 Liu, Y., Endo, Y., Homma, S., Kanno, K., Yaginuma, H. and Fujita, T.,
Ficolin A and ﬁcolin B are expressed in distinct ontogenic patterns and
cell types in the mouse. Mol. Immunol. 2005. 42: 1265–1273.
7 Runza, V. L., Hehlgans, T., Echtenacher, B., Zahringer, U., Schwaeble, W. J.
and Mannel, D. N., Localization of the mouse defense lectin ﬁcolin B in
lysosomes of activated macrophages. J. Endotoxin Res. 2006. 12: 120–126.
8 Garlatti, V., Belloy, N., Martin, L., Lacroix, M., Matsushita, M., Endo, Y.,
Fujita, T. et al., Structural insights into the innate immune recognition
speciﬁcities of L- and H-ﬁcolins. EMBO J. 2007. 26: 623–633.
9 Krarup, A., Mitchell, D. A. and Sim, R. B., Recognition of acetyl-
ated oligosaccharides by human L-ﬁcolin. Immunol. Lett. 2008. 118:
152–156.
10 Krarup, A., Thiel, S., Hansen, A., Fujita, T. and Jensenius, J. C., L-ﬁcolin is
a pattern recognition molecule speciﬁc for acetyl groups. J. Biol. Chem.
2004. 279: 47513–47519.
11 Lynch, N. J., Roscher, S., Hartung, T., Morath, S., Matsushita, M., Maennel,
D. N., Kuraya, M. et al., L-ﬁcolin speciﬁcally binds to lipoteichoic acid, a
cell wall constituent of Gram-positive bacteria, and activates the lectin
pathway of complement. J. Immunol. 2004. 172: 1198–1202.
12 Krarup, A., Sorensen, U. B., Matsushita, M., Jensenius, J. C. and Thiel, S.,
Effect of capsulation of opportunistic pathogenic bacteria on binding of
the pattern recognition molecules mannan-binding lectin, L-ﬁcolin, and
H-ﬁcolin. Infect. Immun. 2005. 73: 1052–1060.
13 Jensen, M. L., Honore, C., Hummelshoj, T., Hansen, B. E., Madsen, H. O.
and Garred, P., Ficolin-2 recognizes DNA and participates in the clearance
of dying host cells. Mol. Immunol. 2007. 44: 856–865.
14 Gout, E., Garlatti, V., Smith, D. F., Lacroix, M., Dumestre-Perard, C.,
Lunardi, T., Martin, L. et al., Carbohydrate recognition properties of
human ﬁcolins: glycan array screening reveals the sialic acid binding
speciﬁcity of M-ﬁcolin. J. Biol. Chem. 2010. 285: 6612–6622.
15 Tsujimura, M., Miyazaki, T., Kojima, E., Sagara, Y., Shiraki, H., Okochi, K.
and Maeda, Y., Serum concentration of Hakata antigen, a member of the
ﬁcolins, is linked with inhibition of Aerococcus viridans growth. Clin. Chim.
Acta 2002. 325: 139–146.
16 Endo, Y., Nakazawa, N., Liu, Y., Iwaki, D., Takahashi, M., Fujita, T.,
Nakata, M. and Matsushita, M., Carbohydrate-binding speciﬁcities of
mouse ﬁcolin A, a splicing variant of ﬁcolin A and ﬁcolin B and their
complex formation with MASP-2 and sMAP. Immunogenetics 2005. 57:
837–844.
17 Endo, Y., Matsushita, M. and Fujita, T., Role of ﬁcolin in innate immunity
and its molecular basis. Immunobiology 2007. 212: 371–379.
18 Wallis, R., Dodds, A. W., Mitchell, D. A., Sim, R. B., Reid, K. B. and
Schwaeble, W. J., Molecular interactions between MASP-2, C4, and C2 and
their activation fragments leading to complement activation via the
lectin pathway. J. Biol. Chem. 2007. 282: 7844–7851.
19 Takahashi, M., Ishida, Y., Iwaki, D., Kanno, K., Suzuki, T., Endo, Y.,
Homma, Y. and Fujita, T., Essential role of mannose-binding lectin-
associated serine protease-1 in activation of the complement factor D. J.
Exp. Med. 2010. 207: 29–37, S21–S23.
20 Megyeri, M., Mako, V., Beinrohr, L., Doleschall, Z., Prohaszka, Z.,
Cervenak, L., Zavodszky, P. and Gal, P., Complement protease MASP-1
Eur. J. Immunol. 2011. 41: 214–223 Umakhanth Venkatraman Girija et al. 222
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euactivates human endothelial cells: PAR4 activation is a link between
complement and endothelial function. J. Immunol. 2009. 183: 3409–3416.
21 Girija, U. V., Dodds, A. W., Roscher, S., Reid, K. B. and Wallis, R.,
Localization and characterization of the mannose-binding lectin (MBL)-
associated-serine protease-2 binding site in rat ﬁcolin-A: equivalent
binding sites within the collagenous domains of MBLs and ﬁcolins.
J. Immunol. 2007. 179: 455–462.
22 Drickamer, K. and Taylor, M. E., Evolving views of protein glycosylation.
Trends Biochem. Sci. 1998. 23: 321–324.
23 Severi, E., Hood, D. W. and Thomas, G. H., Sialic acid utilization by
bacterial pathogens. Microbiology 2007. 153: 2817–2822.
24 Phillips, A. E., Toth, J., Dodds, A. W., Girija, U. V., Furze, C. M., Pala, E.,
Sim, R. B. et al., Analogous interactions in initiating complexes of the
classical and lectin pathways of complement. J. Immunol. 2009. 182:
7708–7717.
25 Wallis, R., Shaw, J. M., Uitdehaag, J., Chen, C. B., Torgersen, D. and
Drickamer, K., Localization of the serine protease-binding sites in the
collagen-like domain of mannose-binding protein: indirect effects of
naturally occurring mutations on protease binding and activation. J. Biol.
Chem. 2004. 279: 14065–14073.
26 Muhlenhoff, M., Eckhardt, M. and Gerardy-Schahn, R., Polysialic acid:
three-dimensional structure, biosynthesis and function. Curr. Opin. Struct.
Biol. 1998. 8: 558–564.
27 Ghoshal, A., Mukhopadhyay, S., Chava, A. K., Gerwig, G. J., Kamerling,
J. P., Chatterjee, M. and Mandal, C., 9-O-acetylated sialic acids enhance
entry of virulent Leishmania donovani promastigotes into macrophages.
Parasitology 2009. 136: 159–173.
28 Soares, R. M., de A. Soares, R. M., Alviano, D. S., Angluster, J., Alviano, C.
S. and Travassos, L. R., Identiﬁcation of sialic acids on the cell surface of
Candida albicans. Biochim. Biophys. Acta 2000. 1474: 262–268.
29 Varki, N. M. and Varki, A., Diversity in cell surface sialic acid
presentations: implications for biology and disease. Lab Invest. 2007. 87:
851–857.
30 Morimoto, N., Nakano, M., Kinoshita, M., Kawabata, A., Morita, M., Oda,
Y., Kuroda, R. and Kakehi, K., Speciﬁc distribution of sialic acids in animal
tissues as examined by LC-ESI-MS after derivatization with 1,2-diamino-
4,5-methylenedioxybenzene. Anal. Chem. 2001. 73: 5422–5428.
31 Garlatti, V., Martin, L., Gout, E., Reiser, J., Fujita, T., Arlaud, G. J., Thielens,
N. M. and Gaboriaud, C., Innate immune sensing: Ligand recognition by
M-ﬁcolin is subject to a pH-dependent conformational switch. Mol.
Immunol. 2007. 44: 3928–3929.
32 Kaufman, R. J., Davies, M. V., Wasley, L. C. and Michnick, D., Improved
vectors for stable expression of foriegn genes in mammalian cells by use
of the untranslated leader sequence from EMC virus. Nucleic Acids Res.
1991. 19: 4485–4490.
33 Chen, C. B. and Wallis, R., Stoichiometry of complexes between
mannose-binding protein and its associated serine proteases. Deﬁning
functional units for complement activation. J. Biol. Chem. 2001. 276:
25894–25902.
34 Chen, C. B. and Wallis, R., Two mechanisms for mannose-binding protein
modulation of the activity of its associated serine proteases. J. Biol. Chem.
2004. 279: 26058–26065.
35 Heise, C. T., Nicholls, J. R., Leamy, C. E. and Wallis, R., Impaired secretion
of rat mannose-binding protein resulting from mutations in the collagen-
like domain. J. Immunol. 2000. 165: 1403–1409.
Abbreviations: GlcNAc: N-acetylglucosamine  MASP: MBL-associated
serine protease  MBL: mannan-binding lectin
Full correspondence: Dr. Russell Wallis, Department of Infection,
Immunity and Inﬂammation, Maurice Shock Building, University of
Leicester, PO Box 138, Leicester LE1 9HN, UK
Fax: 144-116-252-5030
e-mail: rw73@le.ac.uk
Received: 22/4/2010
Revised: 12/8/2010
Accepted: 8/10/2010
Accepted article online: 27/10/2010
Eur. J. Immunol. 2011. 41: 214–223 Molecular immunology 223
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu